Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in <i>ALK</i>-positive NSCLC, Published online: 16 November 2017; doi:10.1038/bjc.2017.395

from Cancer via ola Kala on Inoreader http://ift.tt/2zJJ7Dj
via IFTTT